XBIO
Xenetic Biosciences, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- X Jul 31 Short interest falls 41.4% to 11.3K
- X Aug 14 Short interest jumps 299.3% to 45.2K
- X Aug 31 Short interest falls 55.0% to 20.3K
- R Sep 16 Xenetic Biosciences (XBIO) entered into a definitive share exchange…
- E Sep 16 Trading halt: Trading Halt: XBIO — T1 (News Pending)
- E Sep 16 Trading halt: Halt Resumed: XBIO — trading resumed after T3 (News and Re…
- E Sep 16 Trading halt: Trading Halt: XBIO — T2 (News Released)
- X Sep 30 Short interest falls 42.7% to 12.9K
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q2 2026: 1 added (0 new), 0 trimmed or exited.
- TrendDOWNTREND
37% below its 50-day average. New closing low $1.72 on Oct 23.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | $36.9K |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $57.5K |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | $387.4K |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $29.5K |
| BANK OF AMERICA CORP /DE/ | ADD | $39.00 |
| MORGAN STANLEY | TRIM | $7.00 |
| UBS Group AG | ADD | $6.6K |
| MORGAN STANLEY | DOUBLED | $11.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Apr 2025| Date | Firm | Rating |
|---|---|---|
| Apr 9, 2025 | HC Wainwright & Co. REITERATE | Neutral |
| Mar 20, 2025 | HC Wainwright & Co. REITERATE | Neutral |
| Dec 5, 2024 | HC Wainwright & Co. REITERATE | Neutral |
| Nov 22, 2024 | HC Wainwright & Co. REITERATE | Neutral |
| Aug 20, 2024 | HC Wainwright & Co. REITERATE | Neutral |
| May 16, 2023 | HC Wainwright & Co. DOWNGRADE | Neutral |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 21, 2026 | PARSLOW JAMES F Interim CEO and CFO | AWARD | 100,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026| Sep 16, 2026 | Resumption Scheduled | Resumed |
SecBot reports
7 filings · 1 bullish · 0 bearish · 6 neutral- NEUTRAL 8-KSep 23, 2026
Xenetic Biosciences filed an updated investor presentation detailing its proposed reverse merger…
Monitor stockholder vote on the share exchange and the filing of the S-1 registration statement and proxy statement. Key catalysts include the NucleoCapture sepsis interim analysis (Q4 2027) and the…
- NEUTRAL SC 13GSep 18, 2026
MJL Manager LLC and its control person Michael Liu filed a Schedule 13G disclosing a passive stake…
Monitor for any future amendments to this SC 13G that disclose an actual stake, as the current filing reports zero beneficial ownership. No immediate trading catalyst.
- BULLISH 8-KSep 16, 2026
Xenetic Biosciences (XBIO) entered into a definitive share exchange agreement to acquire all…
This is a de facto reverse merger that provides Santersus with a public listing. The ~85% dilution for existing XBIO holders is extreme, but the combined entity gains a pipeline with two FDA…
- NEUTRAL 8-KAug 7, 2026
Xenetic Biosciences reported Q2 2026 financial results, with royalty revenue increasing 12% YoY to…
This is a pre-revenue biotech with a cash runway of roughly 12-18 months at current burn rates. The strategic review process is a binary catalyst; the absence of any disclosed outcome or new…
All XBIO filing & press-release reports (7)
- 8-K reportSep 23, 2026
- SC 13G reportSep 18, 2026
- 8-K reportSep 16, 2026
- 8-K reportAug 7, 2026
- 8-K reportMay 13, 2026
- 10-K/A reportApr 24, 2026
- 8-K reportApr 24, 2026